Saturday, November 21, 2026
  • Home
  • About us
  • Privacy policy
  • Advertise with us
  • Contact us
Fii News Logo
No Result
View All Result
  • Tenders
  • Projects
  • Markets
  • Manufacturing
  • Investment
  • Technology
  • Exports
  • ASEANFastest Growing
Newsletter
  • Tenders
  • Projects
  • Markets
  • Manufacturing
  • Investment
  • Technology
  • Exports
  • ASEANFastest Growing
Fiinews
No Result
View All Result
Home Health

CSIR-Laxai jointly conduct clinical trial of Niclosamide

Fiinews by Fiinews
June 7, 2021
in Health, Manufacturing, Technology
Reading Time: 2 mins read
A A
0
Laxai Life Sciences Pvt Ltd
0
SHARES
12
VIEWS
LinkedinShare on Twitter

Laxai making API based on IICT’s improved technology

Council of Scientific and Industrial Research (CSIR) is collaborating with Hyderabad-based Laxai Life Sciences Pvt Ltd in Phase-II clinical trial with anti-helminitic drug Niclosamide for treatment of Covid-19. The trial is a multi-centric, phase-II, randomized, open label clinical study to evaluate efficacy, safety and tolerability of Niclosamide for the treatment of hospitalized Covid-19 patients.

Niclosamide has been extensively used in past for treatment of tapeworm’s infection in adults as well as children. The safety profile of this drug has been tested over time and has been found safe for human consumption at different dose levels.

Announcing the collaboration on 6 June 2021, Dr Shekhar C Mande, Director General, CSIR, expressed his happiness over the SEC recommendations to conduct this Phase II clinical trial using Niclosamide, which is generic, affordable drug and easily available in India and therefore can be made available to our population.

Dr Ram Vishwakarma, Advisor to DG-CSIR, pointed out that:

a) in a screen to identify drugs that can inhibit syncytia formation, Niclosamide was identified as a promising repurposed drug by research group from King’s College, London, who collaborated in this project. The syncytia or fused cells observed in the lungs of patients with COVID-19 probably results from the fusogenic activity of the SARS-CoV-2 spike protein and Niclosamide can inhibit syncytia formation.

b) Independently, collaborative research between CSIR-IIIM, Jammu and NCBS, Bangalore has recently demonstrated that Niclosamide is also a potential SARS-CoV2 entry inhibitor blocking the viral entry through pH dependent endocytic pathway. Given these two independent experimental studies, Niclosamide has now emerged as a promising drug candidate for clinical trial in Covid-19 patients.

Dr Srivari Chandrashekhar, Director CSIR-IICT Hyderabad, highlighted that the Active Pharmaceutical Ingredient (API) is being made by Laxai Life Sciences based on improved technology developed at IICT and the lab is a partner in this important clinical trial which could provide cost effective therapeutic options for patients if trial is successful.

Laxai CEO Dr Ram Upadhayaya informed that realizing the potential of Niclosamide, efforts were initiated last year itself to undertake clinical trials. Having received approval from drug regulator, the clinical trial has been initiated this week (announced on 6 June) and is expected to be completed within 8-12 weeks.

Based on successful clinical evidence generated during clinical trials in Indian studies, emergency use authorization may be sought so that more treatment options are available to COVID-19 patients. #health #investment #research #manufacturing /fiinews.com

Tags: Council of Scientific and Industrial ResearchLaxai Life Sciences Pvt Ltd
ShareTweetShare

Related Posts

Microsoft
Technology

Tech: 10cr MSMEs to remain ahead of AI curve

by Fiinews
November 21, 2026
0
20

Microsoft India-Samhita-CGF have convened dialogue with Atal Innovation Mission To ensure that India’s 10 crore MSMEs remain ahead of the...

PIB
Manufacturing

Manufacture: Paswan wants value in agriculture products

by Fiinews
November 21, 2026
0
15

Industry encouraged to develop healthier beverage alternatives, including millets and indigenous ingredients Minister of Food Processing Industries Chirag Paswan has...

DataSwitch

Tech: DataSwitch’s Mathi automates data mapping

November 18, 2026
29
Vikram Solar

Manufacture: TN facility to produce from Dec 2026

November 16, 2026
18
ISNT

Manufacture: Minister wants strengthened NDT ecosystem

November 17, 2026
18
SIH-SMU

Tech: Joshi’s call “think beyond boundaries”

November 16, 2026
32
SBI YONO

Recent News

  • Market: Greaves expands global marine business
  • Market: Polycab strengthens presence in US
  • Project: Diving craft delivered to Navy
  • Tech: 10cr MSMEs to remain ahead of AI curve
  • Manufacture: Paswan wants value in agriculture products

Pages

  • About US
  • ADVERTISE ON FIINEWS.COM
  • CONTACT US
  • EVENTS
  • FII-NEWS.COM PDF ARCHIVE
  • Home
  • News
  • PRIVACY POLICY
  • About
  • Advertise
  • Careers
  • Contact us

© 2026 FIINEWS - Design and developed by 7clicksmedia.

No Result
View All Result
  • Tenders
  • Projects
  • Markets
  • Manufacturing
  • Investment
  • Technology
  • Exports
  • ASEAN

© 2026 FIINEWS - Design and developed by 7clicksmedia.